Histologic Resolution of Melanoma In Situ (Lentigo Maligna) With 5% Imiquimod Cream
- 1 July 2003
- journal article
- other
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 139 (7) , 943-944
- https://doi.org/10.1001/archderm.139.7.943
Abstract
Lentigo maligna (LM) is an in situ melanoma that occurs on the face and other sun-exposed areas. It may histologically extend beyond the clinical borders of the lesion; therefore, obtaining clear surgical margins is difficult. A 55-year-old woman presented with an irregular, brown-to-tan, poorly differentiated, 2.3 × 1.9-cm patch on her right cheek that was accentuated by Wood lamp examination. The hyperpigmented area had been treated 2 years earlier with carbon dioxide laser ablation without biopsy confirmation, but the lesion had recurred and appeared to be darker and larger. A biopsy specimen showed LM (Figure 1). After a thorough discussion of treatment options, including surgical excision, cryotherapy, and radiation therapy, the patient opted for a nonsurgical approach. The discussion to use 5% imiquimod cream, off-label, included a detailed explanation of the risks, potential failure, and departure from the current standard of care. After the patient applied 5% imiquimod cream once or twice a day for 3 months, multiple punch biopsy specimens obtained from the tumor site showed no residual LM (Figure 2). Clinical examination and Wood lamp examination of the area also showed fading of pigmentation and no extension of the lesion.Keywords
This publication has 3 references indexed in Scilit:
- Imiquimod: a novel treatment for lentigo malignaBritish Journal of Dermatology, 2000
- Topical imiquimod treatment of a cutaneous melanoma metastasisJournal of the American Academy of Dermatology, 2000
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999